Company / Free Cash Flow
Roivant Sciences Free Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$766.6M
FY2025
5-year range
-$844.0M / -$557.9M
FY2021-FY2025
Trend
+9.2%
vs FY2024
Sector context
#191 of 194
Health Care
What the data says
Among 194 Health Care companies, Roivant Sciences is in the bottom 2% for free cash flow. Free Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$767M.
Based on SEC 10-K filings.
-$767M in FY2025.
Remained stable around -$767M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 194This company -$766.6M Sector average $470.8M
▼
-262.8% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 9.2% year-over-year.
- Ranks #191 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$766.6M | +9.2% |
| FY2024 | -$844.0M | -10.1% |
| FY2023 | -$766.6M | -37.4% |
| FY2022 | -$557.9M | +19.7% |
| FY2021 | -$695.2M | -24.6% |
| FY2020 | -$557.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026